Cargando…

Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China

BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Zhimin, Lan, Yuanbo, Chen, Ling, Xiang, Min, Peng, Zhiyuan, Zhang, Jianyong, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777635/
https://www.ncbi.nlm.nih.gov/pubmed/31686870
http://dx.doi.org/10.2147/IDR.S222943
_version_ 1783456647608270848
author Cao, Zhimin
Lan, Yuanbo
Chen, Ling
Xiang, Min
Peng, Zhiyuan
Zhang, Jianyong
Zhang, Hong
author_facet Cao, Zhimin
Lan, Yuanbo
Chen, Ling
Xiang, Min
Peng, Zhiyuan
Zhang, Jianyong
Zhang, Hong
author_sort Cao, Zhimin
collection PubMed
description BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of Mycobacterium tuberculosis. PATIENTS AND METHODS: M. tuberculosis clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the pncA gene. RESULTS: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a pncA mutation, and 52 types of pncA mutations were detected from 64 isolates. The prevalence of pncA mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB. CONCLUSION: High prevalence of pncA mutations in clinical isolates of M. tuberculosis from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases.
format Online
Article
Text
id pubmed-6777635
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67776352019-11-04 Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China Cao, Zhimin Lan, Yuanbo Chen, Ling Xiang, Min Peng, Zhiyuan Zhang, Jianyong Zhang, Hong Infect Drug Resist Original Research BACKGROUND: China is one of the high-burden countries for multidrug-resistant tuberculosis (MDR-TB), and pyrazinamide is one of the anti-TB drugs used for the shorter MDR-TB treatment regimen. The aim of this study was to determine the correlation between pncA gene mutations and resistance to four first-line anti-TB drugs as well as treatment history in clinical isolates of Mycobacterium tuberculosis. PATIENTS AND METHODS: M. tuberculosis clinical isolates were collected from 318 in-patients with smear-positive TB between October 2008 and September 2016 at a major hospital in Zunyi, Guizhou Province of China, and used for drug susceptibility testing against four first-line anti-TB drugs. Genomic DNA extracted from clinical isolates was used for PCR amplification and DNA sequencing of the pncA gene. RESULTS: Among 318 clinical isolates, 129 (40.6%), 170 (53.5%), 66 (20.8%) and 109 (34.3%) were resistant to rifampicin, isoniazid, ethambutol and streptomycin respectively. In addition, 124 clinical isolates were MDR-TB and 71.8% of them were previously treated cases. Sequencing results showed that 46.8% of MDR-TB and 2.2% of drug susceptible isolates harbored a pncA mutation, and 52 types of pncA mutations were detected from 64 isolates. The prevalence of pncA mutations in isolates resistant to first-line anti-TB drugs and previously treated TB cases was significantly higher than that in drug-susceptible isolates and new cases of TB. CONCLUSION: High prevalence of pncA mutations in clinical isolates of M. tuberculosis from Zunyi, Guizhou Province of China, is correlated with resistance to four first-line anti-TB drugs, MDR-TB and previously treated TB cases. Dove 2019-09-30 /pmc/articles/PMC6777635/ /pubmed/31686870 http://dx.doi.org/10.2147/IDR.S222943 Text en © 2019 Cao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Cao, Zhimin
Lan, Yuanbo
Chen, Ling
Xiang, Min
Peng, Zhiyuan
Zhang, Jianyong
Zhang, Hong
Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title_full Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title_fullStr Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title_full_unstemmed Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title_short Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China
title_sort resistance to first-line antituberculosis drugs and prevalence of pnca mutations in clinical isolates of mycobacterium tuberculosis from zunyi, guizhou province of china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777635/
https://www.ncbi.nlm.nih.gov/pubmed/31686870
http://dx.doi.org/10.2147/IDR.S222943
work_keys_str_mv AT caozhimin resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT lanyuanbo resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT chenling resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT xiangmin resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT pengzhiyuan resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT zhangjianyong resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina
AT zhanghong resistancetofirstlineantituberculosisdrugsandprevalenceofpncamutationsinclinicalisolatesofmycobacteriumtuberculosisfromzunyiguizhouprovinceofchina